SC 13G: Carisma Therapeutics Inc.

AI Summary

SC 13G filing by Carisma Therapeutics Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value (Titles of Class of Securit

Filing Documents

• tm248577d1_sc13g.htm (SC 13G) — 55KB
• 0001104659-24-033949.txt ( ) — 57KB

(a)

Item 1(a). Name of Issuer: Carisma Therapeutics Inc. (the “Issuer”)

(b)

Item 1(b). Address of Issuer’s Principal Executive Offices: 3675 Market Street, Suite 200 Philadelphia, Pennsylvania 19104

(a)

Item 2(a). Name of Persons Filing: AbbVie Biotechnology Ltd.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: Thistle House, 4 Burnaby Street Hamilton HM 11, Bermuda

(c)

Item 2(c). Citizenship: See response to Item 4 on the cover page.

(d). Titles

Item 2(d). Titles of Classes of Securities: Common stock, $0.001 par value per share (the “Common Stock”)

(e). CUSP

Item 2(e). CUSP Number: 14216R101 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or Dealer registered under Section 15 of the Act. (b) Bank as defined in Section 3(a)(b) of the Act. (c) Insurance company as defined in Section 3(a)(19) of the Act. (d) Investment company registered under Section 8 of the Investment Company Act of 1940. (e) An Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(e). (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) A church plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act. (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J). (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________ Not Applicable. Item 4. (a) Amount beneficially owned: See responses to Item 9 on the cover page. (b) Percent of Class: See responses to Item 11 on the cover page. (c) Number of shares as to which the Reporting Person has: (i) Sole power to vote or to direct the vote: See responses to Item 5 on the cover page. (ii) Shared power to vote or to direct the vote: See responses to Item 6 on the cover page. (iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on the cover page. (iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on the cover page. The Board of Directors of AbbVie Biotechnology Ltd., which consists of Lindsey Bristow, Wayne Klintworth, Jonathan C. Clipper,

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 13, 2024 ABBVIE BIOTECHNOLOGY LTD. By: /s/ Lindsey Bristow Name: Lindsey Bristow Title: Director

View Full Filing

View this SC 13G filing on SEC EDGAR